Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sample size requirements for evaluating a conservative therapy.

R Makuch, R Simon

    Cancer Treatment Reports
    |July 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Estrogen after ischemic stroke: clinical basis and design of the Women's Estrogen for Stroke Trial.

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
    Same author

    Immunodetection and intracellular localization of caldesmon-like proteins in Amoeba proteus.

    Protoplasma·2003
    Same author

    Arrival of afferents and the differentiation of target neurons: studies of developing cholinergic projections to the dentate gyrus.

    Neuroscience·2001
    Same author

    Blood-pressure-lowering treatment.

    Lancet (London, England)·2001
    Same author

    Reversible changes in size of cell nuclei isolated from Amoeba proteus: role of the cytoskeleton.

    Biochemistry and cell biology = Biochimie et biologie cellulaire·2000
    Same author

    Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

    JAMA·2000
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    This study provides formulas for calculating sample size in clinical trials comparing a new treatment to a standard one. It addresses scenarios where the goal is to demonstrate treatment equivalence rather than superiority, aiding researchers in trial design.

    Area of Science:

    • Clinical Trial Design
    • Biostatistics
    • Medical Research Methodology

    Background:

    • Traditional clinical trial sample size determination relies on type I (false positive) and type II (false negative) error rates, and the desired detectable difference.
    • Established convention sets the type I error rate at 0.05 to ensure new therapies are only accepted as superior when definitively proven.
    • A shift in clinical research focuses on demonstrating the equivalence of conservative treatments to standard intensive therapies.

    Purpose of the Study:

    • To present formulas for calculating the necessary sample size in clinical trials aiming to establish treatment equivalence.
    • To provide methods for determining sample size based on investigator-specified criteria for equivalence trials.
    • To analyze the impact of unequal patient allocation between treatment groups on the total sample size.

    Related Experiment Videos

    Main Methods:

    • Development of mathematical formulas for sample size calculation in equivalence-focused clinical trials.
    • Analysis of the percentage increase in total sample size when patient allocation is imbalanced.
    • Formulation based on specified type I and type II error rates and the equivalence margin.

    Main Results:

    • The paper provides specific formulas to guide sample size determination for clinical trials seeking to prove treatment equivalence.
    • Quantification of how unequal patient distribution across treatment arms affects the overall required sample size.
    • Methodology allows investigators to set precise criteria for establishing therapeutic equivalence.

    Conclusions:

    • The proposed formulas offer a robust framework for sample size calculation in equivalence trials, a growing area of clinical research.
    • Understanding the effect of allocation ratios is crucial for efficient trial resource management.
    • This work supports rigorous evaluation of conservative treatments against standard therapies.